Login to Your Account

Other News To Note

Thursday, June 28, 2012

• Compugen Ltd., of Tel Aviv, Israel, said it demonstrated the therapeutic potential of CGEN-15022, a B7/CD28-like membrane protein, as an immune checkpoint target in multiple cancers. The company's results suggested CGEN-15022 is expressed in numerous types of epithelial cancers, including liver, colorectal, lung and ovarian cancers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription